Xencor, Inc Net Income (Loss) Available to Common Stockholders, Diluted
Xencor, Inc (XNCR) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$133.13 million for the 12-month period ending 2023-12-31, per its 10-K/A filed 2025-02-24.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-02-24
- Xencor, Inc net income (loss) available to common stockholders, diluted for the quarter ending 2014-12-31 was -$1.35M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for the quarter ending 2014-09-30 was -$6.28M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for the quarter ending 2014-06-30 was -$5.04M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for the quarter ending 2013-12-31 was -$3.70M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for fiscal 2023 was -$133.13M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for fiscal 2022 was -$55.18M, a 166.78% decline from fiscal 2021.
- Xencor, Inc net income (loss) available to common stockholders, diluted for fiscal 2021 was $82.63M.
- Xencor, Inc net income (loss) available to common stockholders, diluted for fiscal 2020 was -$69.33M, a 357.98% decline from fiscal 2019.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$133.13M 10-K/A · filed 2025-02-24 | -$126.09M 10-K · filed 2024-02-29 | |||
| 2022-12-31 | -$55.18M 10-K/A · filed 2025-02-24 | ||||
| 2021-12-31 | $82.63M 10-K/A · filed 2025-02-24 | ||||
| 2020-12-31 | -$69.33M 10-K · filed 2023-02-27 | ||||
| 2019-12-31 | $26.88M 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | -$70.41M 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | -$38.49M 10-K · filed 2020-02-25 | -$48.92M 10-K · filed 2018-02-28 | |||
| 2016-12-31 | $45.13M 10-K · filed 2019-02-26 | $23.63M 10-K · filed 2018-02-28 | |||
| 2015-12-31 | -$17.59M 10-K · filed 2018-02-28 | ||||
| 2014-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$7.63M derived: sum of 2 quarters · filed 2016-03-08 | -$12.67M derived: sum of 3 quarters · filed 2016-03-08 | -$16.42M 10-K · filed 2016-03-08 | |
| 2014-09-30 | -$6.28M 10-Q · filed 2014-11-10 | -$11.32M derived: sum of 2 quarters · filed 2014-11-10 | -$15.07M 10-Q · filed 2014-11-10 | ||
| 2014-06-30 | -$5.04M 10-Q · filed 2014-08-01 | -$8.79M 10-Q · filed 2014-08-01 | |||
| 2013-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$7.89M derived: sum of 2 quarters · filed 2016-03-08 | -$58.00M derived: sum of 3 quarters · filed 2016-03-08 | -$60.26M 10-K · filed 2016-03-08 | |
| 2013-09-30 | -$4.18M 10-Q · filed 2014-11-10 | -$54.29M derived: sum of 2 quarters · filed 2014-11-10 | -$56.56M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | -$50.11M 10-Q · filed 2014-08-01 | -$54.72M 10-Q · filed 2014-08-01 | |||
| 2012-12-31 | -$8.59M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |